Kennedy Capital Management LLC Purchases New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Kennedy Capital Management LLC purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 60,494 shares of the company's stock, valued at approximately $1,173,000. Kennedy Capital Management LLC owned 0.17% of Oruka Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP purchased a new stake in Oruka Therapeutics during the third quarter valued at about $2,013,000. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at approximately $343,000. Franklin Resources Inc. bought a new position in Oruka Therapeutics in the 3rd quarter worth approximately $17,661,000. China Universal Asset Management Co. Ltd. bought a new position in Oruka Therapeutics in the 4th quarter worth approximately $144,000. Finally, AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics in the 4th quarter valued at approximately $119,000. Institutional investors own 56.44% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ORKA shares. Wolfe Research began coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price on the stock. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Oruka Therapeutics has an average rating of "Buy" and an average target price of $39.86.

Insider Transactions at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the acquisition, the insider now owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. This represents a 2.19 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders purchased 98,339 shares of company stock valued at $1,128,456. Insiders own 22.67% of the company's stock.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA traded up $0.61 on Friday, hitting $9.22. The company's stock had a trading volume of 150,023 shares, compared to its average volume of 237,939. The company has a market capitalization of $345.02 million, a PE ratio of -1.47 and a beta of 0.47. The company has a 50-day simple moving average of $10.19 and a 200 day simple moving average of $17.47. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.19. On average, equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.